eMedicine Specialties > Dermatology > Environmental

Brown Recluse Spider Bite

Author: Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Contributor Information and Disclosures

Updated: Jun 10, 2009

Introduction

Background

The brown recluse spider (Loxosceles reclusa; see Media Files 1-2) is the most prevalent of the Loxosceles species in the United States. All Loxosceles species have the potential to inflict injury to varying degrees. Seen predominantly in the south central part of the United States, the brown recluse spider has been discovered as far north as Illinois and on both coasts. Other members of the Loxosceles species are found throughout the world.

Brown recluse spider. Courtesy of US Centers for ...

Brown recluse spider. Courtesy of US Centers for Disease Control and Prevention.

Brown recluse spider. Courtesy of US Centers for ...

Brown recluse spider. Courtesy of US Centers for Disease Control and Prevention.



Brown recluse spider. Courtesy of US Centers for ...

Brown recluse spider. Courtesy of US Centers for Disease Control and Prevention.

Brown recluse spider. Courtesy of US Centers for ...

Brown recluse spider. Courtesy of US Centers for Disease Control and Prevention.


Incidents involving the brown recluse spider usually occur in summer months as a consequence of the spider's activity patterns. Bites are rare, even in houses heavily infested with brown recluse spiders; therefore, a diagnosis of brown recluse spider bite is quite unlikely in areas that lack significant populations of Loxosceles spiders.

Bites of the brown recluse spider can cause a condition termed necrotic arachnidism, which begins with the development of an eschar at the bite site, followed by tissue necrosis and skin sloughing. Several groups of spiders have been linked to necrotic skin lesions, but recluse spiders cause most of these lesions. While most recluse bites heal uneventfully, some have a protracted course, with the wound taking months to resolve completely.

The brown recluse spider commonly is known as the fiddle-back or violin spider because of the distinguishing mark on its cephalothorax. The dull yellow-to-brown coloring of its body further distinguishes the brown recluse. It has a small body relative to its leg span, and 3 pairs of eyes rather than the 4 pairs typical of other spiders. The reclusive mannerism is demonstrated by the locations in which the spiders are encountered. They prefer dark, dry, and undisturbed locations, such as the undersides of logs, boards, and rocks and inside barns and garages. Genital bites have been seen on patients using outhouses. Within homes they are found in attics, closets, and storage areas for bedding, clothing, and furniture. Both the male and female spider can envenomate.

In 2008, Vetter and Rust1 reported on the refugia preferences of the brown recluse spider. In this study, brown recluse spiders were offered a variety of refugia in order to determine whether they preferred certain types of refugia spaces. Observations revealed that some individual spiders always preferred the same refugium for the entire study period; other individuals changed refugia every 2-3 d. The degree of starvation over the period tested did not affect the propensity to switch refugia. This type of research may aid in the development of novel control measures for Loxosceles spiders.

Other eMedicine articles from different specialty perspectives include Spider Envenomation, Brown Recluse (emergency medicine) and Spider Bites (ophthalmology).

Pathophysiology

Bites and envenomation range from a mild, local, urticarial reaction to full-thickness necrosis.

The venom volume is minute, about 4 µL, with 65-100 mcg of protein. The venom contains alkaline phosphatase, 5'ribonucleotide phosphohydrolase, esterase, lipase, hyaluronidase, and, most importantly, sphingomyelinase D2. Sphingomyelinase D2 is responsible for calcium-dependent direct erythrocyte lysis. The degree of hemolysis is individually variable from 20% to more than 95%.

Cutaneous necrosis is completely dependent on activation of neutrophils. In rabbit studies, neutrophil infiltration occurs at 6 hours. Neutrophils significantly accumulate at 24-72 hours, preceding skin necrosis and ulceration. This explains why early dapsone initiation may be important to limit necrosis in bites destined for that reaction.

Frequency

United States

In 1994, 1835 brown recluse spider bites were reported to poison control centers nationwide. In South Carolina alone, physicians diagnosed 478 brown recluse spider bites in 1990 and 738 in 2004.2 However, the number of brown recluse spider bites reportedly diagnosed in South Carolina greatly outnumbers the verified brown recluse specimens that have been collected in the state, a pattern of bite diagnoses outnumbering verified brown recluse specimens noted in other areas outside of this spider's known endemic range. The veracity of publications reporting skin disease caused by the brown recluse spider, L reclusa, has been questioned by others too, as many of these articles contain inadequate documentation of Loxosceles bites.3,4,5 The same has been postulated in the US state of Georgia.6 Bite diagnoses should be made with caution.

International

The incidence of bites and envenomation is unknown.

Mortality/Morbidity

  • Death is uncommon. Most patient occurrences documented with fatal envenomation have involved hematologic disorders in children.
  • Systemic loxoscelism is unusual, especially in adults. Cutaneous loxoscelism is not uncommon with bites. Few envenomations, perhaps less than 10%, result in severe skin necrosis or other systemic manifestations.

Age

Systemic loxoscelism is most common in children.7

Clinical

History

  • Constitutional symptoms, including a macular, papular, urticarial, vasculitic, petechial, scarlatiniform, or morbilliform eruption: The brown recluse spider bite may appear as generalized exanthem, show localized necrosis, and, rarely, have potentially lethal systemic involvement.8
  • Hematologic disorders, such as hemolysis,9 hemoglobinuria, thrombocytopenia, disseminated intravascular coagulation, methemoglobinemia, and shock (rare but serious complications)
  • Fever
  • Headache
  • Malaise
  • Arthralgia and rhabdomyolysis
  • Nausea
  • Vomiting
  • Renal failure

Physical

The bite typically is painless, and findings of a central papule and associated erythema may not be seen for 6-12 hours. Few envenomations, perhaps less than 10%, result in severe skin necrosis or other systemic manifestations.

  • Wounds destined for necrosis usually show signs of progression within 48-72 hours of the bite.
  • Central blistering with a surrounding gray-to-purple discoloration of the skin may be seen at the bite site.
  • A surrounding ring of blanched skin is itself surrounded by a large area of asymmetric erythema leading to the typical "red, white, and blue" sign of a brown recluse bite. At this stage of evolution, these bites may be associated with significant pain related to incipient necrosis of skin and subcutaneous tissues. The resultant eschar and ulceration may take months to resolve.


Within an hour, the bite area swelled to the size...

Within an hour, the bite area swelled to the size of a quarter. The area turned blue and dark red by the evening of the first day, exceeding the boundaries of a circle drawn around the area of initial swelling by the patient's physician. Courtesy of Dale Losher.

Within an hour, the bite area swelled to the size...

Within an hour, the bite area swelled to the size of a quarter. The area turned blue and dark red by the evening of the first day, exceeding the boundaries of a circle drawn around the area of initial swelling by the patient's physician. Courtesy of Dale Losher.

  • Note that patients who are destined for a severe reaction usually develop key signs within 6-12 hours, such as bullae formation, cyanosis, and hyperesthesia.
  • Areas with increased adipose tissue, such as the thighs, buttocks, and abdomen, are more likely to undergo severe necrosis than bites occurring at other sites.


The third day after the bite. The skin continues ...

The third day after the bite. The skin continues to die. Courtesy of Dale Losher.

The third day after the bite. The skin continues ...

The third day after the bite. The skin continues to die. Courtesy of Dale Losher.



Another view of the wound 3 days after the bite. ...

Another view of the wound 3 days after the bite. Courtesy of Dale Losher.

Another view of the wound 3 days after the bite. ...

Another view of the wound 3 days after the bite. Courtesy of Dale Losher.



Nine days after the bite. The patient endured 8 d...

Nine days after the bite. The patient endured 8 days with an open wound to drain the spider's toxins and needed intravenous antibiotics and pain medication almost 24 h/d. Courtesy of Dale Losher.

Nine days after the bite. The patient endured 8 d...

Nine days after the bite. The patient endured 8 days with an open wound to drain the spider's toxins and needed intravenous antibiotics and pain medication almost 24 h/d. Courtesy of Dale Losher.



Eleven days after the bite. A 5-inch wide area of...

Eleven days after the bite. A 5-inch wide area of dead tissue was excised, necessitating skin grafting. Courtesy of Dale Losher.

Eleven days after the bite. A 5-inch wide area of...

Eleven days after the bite. A 5-inch wide area of dead tissue was excised, necessitating skin grafting. Courtesy of Dale Losher.



Brown recluse spider bite. Waiting to see skin gr...

Brown recluse spider bite. Waiting to see skin graft results 38 days after the bite. Courtesy of Dale Losher.

Brown recluse spider bite. Waiting to see skin gr...

Brown recluse spider bite. Waiting to see skin graft results 38 days after the bite. Courtesy of Dale Losher.



Skin graft results 38 days after the bite. Courte...

Skin graft results 38 days after the bite. Courtesy of Dale Losher.

Skin graft results 38 days after the bite. Courte...

Skin graft results 38 days after the bite. Courtesy of Dale Losher.



View of healed wound approximately 10 months afte...

View of healed wound approximately 10 months after bite. Courtesy of Dale Losher.

View of healed wound approximately 10 months afte...

View of healed wound approximately 10 months after bite. Courtesy of Dale Losher.

More on Brown Recluse Spider Bite

Overview: Brown Recluse Spider Bite
Differential Diagnoses & Workup: Brown Recluse Spider Bite
Treatment & Medication: Brown Recluse Spider Bite
Follow-up: Brown Recluse Spider Bite
Multimedia: Brown Recluse Spider Bite
References

References

  1. Vetter RS, Rust MK. Refugia preferences by the spiders Loxosceles reclusa and Loxosceles laeta (Araneae: Sicariidae). J Med Entomol. Jan 2008;45(1):36-41. [Medline].

  2. Frithsen IL, Vetter RS, Stocks IC. Reports of envenomation by brown recluse spiders exceed verified specimens of Loxosceles spiders in South Carolina. J Am Board Fam Med. Sep-Oct 2007;20(5):483-8. [Medline].

  3. Vetter RS. Arachnids submitted as suspected brown recluse spiders (Araneae: Sicariidae): Loxosceles spiders are virtually restricted to their known distributions but are perceived to exist throughout the United States. J Med Entomol. Jul 2005;42(4):512-21. [Medline].

  4. Vetter RS, Swanson DL. Arthropods in dermatology: errors in arachnology. J Am Acad Dermatol. May 2005;52(5):923. [Medline].

  5. Vetter RS, Swanson DL. Of spiders and zebras: publication of inadequately documented loxoscelism case reports. J Am Acad Dermatol. Jun 2007;56(6):1063-4. [Medline].

  6. Vetter RS, Hinkle NC, Ames LM. Distribution of the brown recluse spider (Araneae: Sicariidae) in Georgia with comparison to poison center reports of envenomations. J Med Entomol. Jan 2009;46(1):15-20. [Medline].

  7. Elbahlawan LM, Stidham GL, Bugnitz MC, Storgion SA, Quasney MW. Severe systemic reaction to Loxosceles reclusa spider bites in a pediatric population. Pediatr Emerg Care. Mar 2005;21(3):177-80. [Medline].

  8. Robb CW, Hayes BB, Boyd AS. Generalized vasculitic exanthem following Loxosceles reclusa envenomation. J Cutan Pathol. Jun 2007;34(6):513-4. [Medline].

  9. Blackall DP. Transfusion medicine illustrated: intravascular hemolysis with brown recluse spider envenomation. Transfusion. Nov 2004;44(11):1543. [Medline].

  10. Elston DM, Eggers JS, Schmidt WE, et al. Histological findings after brown recluse spider envenomation. Am J Dermatopathol. Jun 2000;22(3):242-6. [Medline].

  11. Carlton PK Jr. Brown recluse spider bite? Consider this uniquely conservative treatment. J Fam Pract. Feb 2009;58(2):E1-6. [Medline].

  12. Elston DM, Miller SD, Young RJ 3rd, Eggers J, McGlasson D, Schmidt WH. Comparison of colchicine, dapsone, triamcinolone, and diphenhydramine therapy for the treatment of brown recluse spider envenomation: a double-blind, controlled study in a rabbit model. Arch Dermatol. May 2005;141(5):595-7. [Medline].

  13. Maynor ML, Moon RE, Klitzman B, Fracica PJ, Canada A. Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy. Acad Emerg Med. Mar 1997;4(3):184-92. [Medline].

  14. Strain GM, Snider TG, Tedford BL, Cohn GH. Hyperbaric oxygen effects on brown recluse spider (Loxosceles reclusa) envenomation in rabbits. Toxicon. 1991;29(8):989-96. [Medline].

  15. Tutrone WD, Green KM, Norris T, Weinberg JM, Clarke D. Brown recluse spider envenomation: dermatologic application of hyperbaric oxygen therapy. J Drugs Dermatol. Jul-Aug 2005;4(4):424-8. [Medline].

  16. Anderson PC. Missouri brown recluse spider: a review and update. Mo Med. Jul 1998;95(7):318-22. [Medline].

  17. Blackman JR. Spider bites. J Am Board Fam Pract. Jul-Aug 1995;8(4):288-94. [Medline].

  18. Carbonaro PA, Janniger CK, Schwartz RA. Spider bite reactions. Cutis. Nov 1995;56(5):256-9. [Medline].

  19. Carbonaro PA, Schwartz RA. Recluse spider bites: a review of reactions and treatments. Chron Dermatol. 1996;6:817-26.

  20. Donepudi SK, Ahmed KA, Stocks RM, Nelson D, Thompson JW. Aural involvement in loxoscelism: case report and literature review. Int J Pediatr Otorhinolaryngol. Nov 2005;69(11):1559-61. [Medline].

  21. Elston DM. Systemic manifestations and treatment of brown recluse spider bites. Cutis. Dec 2004;74(6):336, 338, 340. [Medline].

  22. Forks TP. Brown recluse spider bites. J Am Board Fam Pract. Nov-Dec 2000;13(6):415-23. [Medline].

  23. Futrell JM. Loxoscelism. Am J Med Sci. Oct 1992;304(4):261-7. [Medline].

  24. King LE Jr, Rees RS. Treatment of brown recluse spider bites. J Am Acad Dermatol. Apr 1986;14(4):691-2. [Medline].

  25. Lane DR, Youse JS. Coombs-positive hemolytic anemia secondary to brown recluse spider bite: a review of the literature and discussion of treatment. Cutis. Dec 2004;74(6):341-7. [Medline].

  26. Lowry BP, Bradfield JF, Carroll RG, Brewer K, Meggs WJ. A controlled trial of topical nitroglycerin in a New Zealand white rabbit model of brown recluse spider envenomation. Ann Emerg Med. Feb 2001;37(2):161-5. [Medline].

  27. Mack RB. The bite of the spider woman. Loxosceles reclusa (the brown recluse). N C Med J. 1992;53(5):200-3. [Medline].

  28. Madion DC, Marshall MK, Jenkins CD, Kushner GM. Brown recluse spider bite to the face. J Oral Maxillofac Surg. Dec 2005;63(12):1774-8. [Medline].

  29. Maso MJ, Lin RY, Bagley MP, Cohen PJ, Schwartz RA. Immunopathological changes after multiple spider bites. Contact Dermatitis. Aug 1987;17(2):65-8. [Medline].

  30. Masters EJ, King LE Jr. Differentiating loxoscelism from Lyme disease. Emerg Med. 1994;26:47-9.

  31. Mold JW, Thompson DM. Management of brown recluse spider bites in primary care. J Am Board Fam Pract. Sep-Oct 2004;17(5):347-52. [Medline].

  32. Phillips S, Kohn M, Baker D, et al. Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med. Mar 1995;25(3):363-8. [Medline].

  33. Rees R, Campbell D, Rieger E, King LE. The diagnosis and treatment of brown recluse spider bites. Ann Emerg Med. Sep 1987;16(9):945-9. [Medline].

  34. Rees RS, Altenbern DP, Lynch JB, King LE Jr. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg. Nov 1985;202(5):659-63. [Medline].

  35. Salm RJ, Fee MJ, Giacopelli JA, Granoff DP, Park EY. Brown recluse spider bite. Two case reports and review. J Am Podiatr Med Assoc. Jan 1998;88(1):37-41. [Medline].

  36. Sams HH, Dunnick CA, Smith ML, King LE Jr. Necrotic arachnidism. J Am Acad Dermatol. Apr 2001;44(4):561-73; quiz 573-6. [Medline].

  37. Steen CJ, Carbonaro PA, Schwartz RA. Arthropods in dermatology. J Am Acad Dermatol. Jun 2004;50(6):819-42, quiz 842-4. [Medline].

  38. Swanson DL, Vetter RS. Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med. Feb 17 2005;352(7):700-7. [Medline].

  39. Vetter RS, Bush SP. Additional considerations in presumptive brown recluse spider bites and dapsone therapy. Am J Emerg Med. Oct 2004;22(6):494-5. [Medline].

  40. Wasserman GS. Wound care of spider and snake envenomations. Ann Emerg Med. Dec 1988;17(12):1331-5. [Medline].

  41. Wendell RP. Brown recluse spiders: a review to help guide physicians in nonendemic areas. South Med J. May 2003;96(5):486-90. [Medline].

  42. Wilson DC, King LE. Spiders and spider bites. Dermatol Clin. Apr 1990;8(2):277-86. [Medline].

  43. Wilson JR, Hagood CO Jr, Prather ID. Brown recluse spider bites: a complex problem wound. A brief review and case study. Ostomy Wound Manage. Mar 2005;51(3):59-66. [Medline].

  44. Wong RC, Hughes SE, Voorhees JJ. Spider bites. Arch Dermatol. Jan 1987;123(1):98-104. [Medline].

  45. Wright SW, Wrenn KD, Murray L, Seger D. Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med. Jul 1997;30(1):28-32. [Medline].

Further Reading

Keywords

brown recluse spider bite, brown recluse spider, spider bite, Loxosceles reclusa, L reclusa, Loxosceles species, insect bite, arachnid, arachnid bitenecrotic arachnidism, necrotic skin lesions, fiddle-back spider, violin spider

Contributor Information and Disclosures

Author

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Medical Editor

Abby S Van Voorhees, MD, Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Abby S Van Voorhees, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, National Psoriasis Foundation, Phi Beta Kappa, Sigma Xi, and Women's Dermatologic Society
Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Genentech Honoraria Consulting; Incyte Grant/research funds Other; Warner Chilcott Honoraria Consulting; Merck Salary Management position; Abbott  Speaking and teaching

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Managing Editor

Jeffrey J Miller, MD, Associate Professor of Dermatology, Penn State University College of Medicine; Staff Dermatologist, Penn State Milton S Hershey Medical Center
Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Professors of Dermatology, North American Hair Research Society, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds None; Genentech Consulting fee Consulting; Centocor Consulting fee Consulting; Centocor Grant/research funds None; Covance Consulting fee Consulting; Shire  Consulting

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.